The First Affiliated Hospital of Anhui University of Chinese Medicine, First Clinical Medical College, Hefei, Anhui, China.
Department of Rheumatism Immunity, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
Front Immunol. 2024 Sep 23;15:1465442. doi: 10.3389/fimmu.2024.1465442. eCollection 2024.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic and symmetrical polyarthritis. RA patients often experience inflammatory reaction and hypercoagulable state, which together affect the self-perception of patient (SPP). Currently, inhibiting inflammation and hypercoagulable state are common treatment methods for alleviating RA symptoms. Xinfeng Capsules (XFC) has a long history of treating RA, and can effectively improve the inflammatory response and hypercoagulable state of RA. However, the potential mechanisms have not yet been determined.
This study elucidated the action mechanism of XFC in RA inflammation and hypercoagulability through the lncDSCR9/RPLP2/PI3K/AKT axis.
Clinical observations indicated that there was a strong link between XFC therapy and improvements in inflammatory and coagulation biomarkers, as well as SPP among RA patients. The subsequent network pharmacology analysis results identified the PI3K/AKT signaling pathway as a potential mediator for XFC treatment of RA. Furthermore, clinical validation and sequencing results revealed that lncRNA DSCR9 expression (a gene implicated in inflammation and coagulation) was negatively correlated with clinical markers of inflammation and coagulation, while positively correlated with SF-36 indicators. Notably, XFC treatment remarkably upregulated lncRNA DSCR9 expression and downregulated PI3K and AKT expressions, showing opposite expression trends to the untreated cases.The regulatory effect of XFC on the lncRNA DSCR9/RPLP2/PI3K/AKT axis in RA was investigated using techniques such as RNA pull-down assay, Western blot analysis, RT-PCR, and EdU assay. Moreover, the administration of the PI3K/AKT agonist RMH can counteract the effects of XFC on p-PI3K, p-AKT, inflammation, and hypercoagulability, reinforcing the role of pathway. Finally, animal studies utilizing HE staining and transmission electron microscopy (TEM) demonstrated that XFC notably decreased PI3K and AKT expressions in adjuvant-induced arthritis (AA) rats, mitigated inflammation and hypercoagulability, and enhanced the ultrastructure of synovial cells. These findings underscored the potential mechanisms of XFC in the treatment of RA.
Regulating the lncRNA DSCR9/RPLP2/PI3K/AKT axis may be an important mechanism by which XFC improved RA inflammatory response and hypercoagulable state.
类风湿关节炎(RA)是一种以慢性和对称性多关节炎为特征的系统性自身免疫性疾病。RA 患者常伴有炎症反应和高凝状态,两者共同影响患者的自我感知(SPP)。目前,抑制炎症反应和高凝状态是缓解 RA 症状的常用治疗方法。新风胶囊(XFC)治疗 RA 历史悠久,能有效改善 RA 的炎症反应和高凝状态。但其潜在机制尚不清楚。
本研究通过 lncDSCR9/RPLP2/PI3K/AKT 轴阐明 XFC 在 RA 炎症和高凝中的作用机制。
临床观察表明,XFC 治疗与 RA 患者炎症和凝血生物标志物以及 SPP 的改善之间存在很强的关联。随后的网络药理学分析结果表明,PI3K/AKT 信号通路可能是 XFC 治疗 RA 的潜在中介。此外,临床验证和测序结果表明,lncRNA DSCR9 表达(与炎症和凝血相关的基因)与炎症和凝血的临床标志物呈负相关,而与 SF-36 指标呈正相关。值得注意的是,XFC 治疗可显著上调 lncRNA DSCR9 表达,下调 PI3K 和 AKT 表达,与未治疗病例呈相反的表达趋势。通过 RNA 下拉实验、Western blot 分析、RT-PCR 和 EdU 实验等技术研究了 XFC 对 RA 中 lncRNA DSCR9/RPLP2/PI3K/AKT 轴的调节作用。此外,PI3K/AKT 激动剂 RMH 的给药可以拮抗 XFC 对 p-PI3K、p-AKT、炎症和高凝的作用,增强了该通路的作用。最后,利用 HE 染色和透射电镜(TEM)观察到,XFC 可显著降低佐剂诱导关节炎(AA)大鼠的 PI3K 和 AKT 表达,减轻炎症和高凝状态,改善滑膜细胞的超微结构。这些发现强调了 XFC 在治疗 RA 中的潜在机制。
调节 lncRNA DSCR9/RPLP2/PI3K/AKT 轴可能是 XFC 改善 RA 炎症反应和高凝状态的重要机制。